Insider · CIK 0001721108
A. Sinclair Dunlop
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Nov 21, 2023, latest Oct 15, 2025.
In brief
A. Sinclair Dunlop files SEC Form 4 as director at APLS (Apellis Pharmaceuticals, Inc.). Since Nov 21, 2023, A. Sinclair Dunlop has reported 0 open-market buys worth $0 and 6 open-market sells worth $5.2M, the latest filed on Oct 15, 2025.
A track record needs three past buys with six months of prices behind them; A. Sinclair Dunlop has 0, so none is measured yet.
The newest scored trade: sold $738k of APLS on Oct 10, 2025, filed Oct 15, 2025, scored 51 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $738k.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | Apellis Pharmaceuticals, Inc. | $738k 31,092 shares | -89% | - | |
| 34Weak | Apellis Pharmaceuticals, Inc. | $702k 31,092 shares | -48% | - | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | $714k 31,092 shares | -31% | - | |
| 60Notable | Apellis Pharmaceuticals, Inc. | $1.5M 24,000 shares | -11% | - | |
| 55Moderate | Apellis Pharmaceuticals, Inc. | $1.2M 24,000 shares | -10% | - | |
| 47Moderate | Apellis Pharmaceuticals, Inc. | $445k 8,894 shares | -7% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 19, 2025 | APLS Apellis Pharmaceuticals, Inc. | 93,276 0.07% of outstanding | $2.1M | Sep 19, 2025 | none |
| Dec 1, 2023 | APLS Apellis Pharmaceuticals, Inc. | 24,000 0.02% of outstanding | $1.3M | Dec 1, 2023 | $1.2M |
| Nov 17, 2023 | APLS Apellis Pharmaceuticals, Inc. | 8,894 0.01% of outstanding | $445k | Nov 17, 2023 | none |
| Nov 9, 2023 | APLS Apellis Pharmaceuticals, Inc. | 24,000 0.02% of outstanding | $1.2M | Nov 9, 2023 | none |
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | UTender of shares Common Stock | -161,567 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -3,062 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -5,744 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -7,961 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -3,544 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -14,684 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -27,600 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -11,199 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -8,554 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -7,441 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -27,600 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -5,748 | - | - | 0 | May 14, 2026 |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +7,961 | $0.00 | $0 | 161,567 | Jan 5, 2026 |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,684 | $0.00 | $0 | 14,684 | Jan 5, 2026 |
| Jun 24, 2025 | APLS Apellis Pharmaceuticals, Inc. | JOther Common Stock10b5-1 | -4,787 | $0.00 | $0 | 153,606 | Oct 15, 2025 |
| Oct 10, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $23.72 | $738k | 3,837 | Oct 15, 2025 |
| Oct 10, 2025 | APLS Apellis Pharmaceuticals, Inc. | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 0 | Oct 15, 2025 |
| Sep 30, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $22.58 | $702k | 33,979 | Oct 2, 2025 |
| Sep 30, 2025 | APLS Apellis Pharmaceuticals, Inc. | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 30,142 | Oct 2, 2025 |
| Sep 19, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $22.95 | $714k | 68,908 | Sep 19, 2025 |
| Sep 19, 2025 | APLS Apellis Pharmaceuticals, Inc. | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 65,071 | Sep 19, 2025 |
| Jan 1, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +6,267 | $0.00 | $0 | 158,393 | Jan 3, 2025 |
| Jan 1, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +11,199 | $0.00 | $0 | 11,199 | Jan 3, 2025 |
| Dec 14, 2023 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,274 | $13.19 | $83k | 128,677 | Dec 15, 2023 |
| Dec 14, 2023 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -6,274 | $0.00 | $0 | 7,000 | Dec 15, 2023 |
| Dec 1, 2023 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex) | -24,000 | $61.14 | $1.5M | 192,679 | Dec 5, 2023 |
| Nov 17, 2023 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -8,894 | $49.99 | $445k | 122,403 | Nov 21, 2023 |
| Oct 17, 2023 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex) | -24,000 | $49.00 | $1.2M | 216,679 | Nov 21, 2023 |
Questions about A. Sinclair Dunlop
Answered from the filings on this page, as of the latest one.
Is A. Sinclair Dunlop buying or selling?
In the last 12 months A. Sinclair Dunlop reported 0 open-market buys worth $0 and 1 open-market sell worth $738k on SEC Form 4; the latest was sold $738k of APLS on Oct 10, 2025. Grants, option exercises and tax withholding are not counted.
How did A. Sinclair Dunlop's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and A. Sinclair Dunlop has 0.
Where does A. Sinclair Dunlop file Form 4?
A. Sinclair Dunlop has filed Form 4 at APLS (Apellis Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.